<DOC>
	<DOCNO>NCT01212367</DOCNO>
	<brief_summary>This research study activate immune system use gene transfer . Gene transfer involve insert specially design gene cancer cell . A gene part genetic code instructs cell body produce specific compound ( protein ) important makeup function cell . The study hypothesis repeat dos SCH 721015 give three day interval would result gene transfer .</brief_summary>
	<brief_title>Intrapleural Gene Transfer Pleural Mesothelioma</brief_title>
	<detailed_description>Ad.hIFN-α ( SCH 721015 , adenoviral-mediated interferon alpha ) replication-defective recombinant adenoviral vector contain human interferon-alpha ( hIFN-alpha ) gene . This Phase I study design evaluate safety maximum tolerate dose ( MTD ) two dose Ad.hIFN-alpha injected pleural ( intrapleural , IP ) give 4 day apart subject pleural mesothelioma . Subjects meet eligibility pleural catheter place 2 week prior first dose . Subjects admit research center Days 1 4 dose overnight observation . Subjects followed-up outpatient total 6 month . Radiographic evaluation repeat Day 64 6 month . The pleural catheter remove necessary .</detailed_description>
	<mesh_term>Mesothelioma</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>evidence progressive disease standard first line treatment mesothelioma ; OR patient refused standard first line treatment mesothelioma evaluable disease No radiotherapy and/or treatment chemotherapeutic , cytotoxic , immunologic agent within 14 day prior infusion IFNα vector Must pleural space involve tumor accessible pleural catheter insertion FEV1 &gt; 1 liter 40 % predict value Must antiadenoviral neutralizing antibody titer equal less 1:1000 . This measure Penn Vector Core Presence HIV Hepatitis B infection Use concurrent systemic steroid , immunosuppressive , medication directly indirectly suppress immune system Presence lifethreatening illness , unstable angina , severe oxygen dependence , significant chronic obstructive pulmonary disease ( COPD ) , end stage liver renal disease Presence untreated brain metastasis Prior bone marrow stem cell transplant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Gene transfer</keyword>
	<keyword>Immunology</keyword>
	<keyword>Cancer</keyword>
</DOC>